Can CSF biomarkers predict future MS disease activity and severity?

Area of Science:

• Neurology
• Biomarker Discovery
• Disease Prognosis

Background:

• Multiple sclerosis (MS) is a complex neurological disorder with variable disease trajectories.
• Current disease-modifying treatments for MS vary in efficacy and risk.
• Accurate prognostication is essential for personalized treatment selection in MS.

Purpose of the Study:

• To review cerebrospinal fluid (CSF) and blood biomarkers for predicting severe disease and disability in MS patients.
• To identify biomarkers that differentiate high-risk MS individuals from those with a more benign disease course.

Main Methods:

• Systematic review of published literature.
• Focused on studies reporting biomarkers with predictive value in multiple sclerosis.
• Analysis of CSF and blood samples for specific protein markers.

Main Results:

• Cerebrospinal fluid oligoclonal bands (IgG, IgM), high IgG index, and elevated kappa light chains are associated with worse MS prognosis.
• CSF neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and YKL-40 correlate with clinical progression and neurodegeneration.
• Serum NfL (sNfL) shows early promise in predicting brain volume loss in MS.

Conclusions:

• CSF and blood biomarkers hold significant potential for stratifying MS patients based on prognosis.
• These biomarkers can guide treatment decisions, balancing efficacy with risk.
• Further research into blood-based biomarkers like sNfL is warranted for MS prognostication.